Loading...
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ(25‐35)‐induced anxiety and cognitive deficits in a mouse model
AIMS: Recently, histone deacetylase (HDAC) inhibitors are considered a possible therapeutic strategy in Alzheimer's disease (AD). However, HDACi treatments exhibit diverse functions with unfavorable effects in AD. Thus, the development of selective HDACi without side effects is urgently needed....
Na minha lista:
| Udgivet i: | CNS Neurosci Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488906/ https://ncbi.nlm.nih.gov/pubmed/29978554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13029 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|